Coral Olazagasti/X
Jun 1, 2025, 09:07
Coral Olazagasti: Exciting Progress in Treating Recurrent Metastatic Nasopharyngeal Cancer
Coral Olazagasti, Assistant professor at the Sylvester Cancer Center at University of Miami, shared a post on X:
“Exciting progress in treating recurrent metastatic nasopharyngeal cancer!
The first-ever clinical trial of ADCs shows a 40% overall response rate, offering hope for patients with limited options.
A step forward!”
Olazagasti highlighted encouraging results from the first antibody-drug conjugate (ADC) trial in recurrent metastatic nasopharyngeal cancer, reporting a 40% overall response rate.
More posts featuring Coral Olazagasti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20